Just imagine if doctors could offer you customized breast cancer treatment. A remarkable discovery of a novel gene by scientists from Singapore, Canada, USA, UK, New Zealand and Australia in a collaborative effort has made this possible. The newly found predictive marker, DP103 could help doctors to classify each breast cancer patient and customize a unique treatment regimen for them. DP103 is a gene activated in metastatic breast cancer, which expresses two sets of unfavorable proteins – one leads to metastasis (spread of cancer) and the other causes patients to be unresponsive to chemotherapy.
Consequently, doctors can examine the DP103 levels and predict the probability of metastasis and whether a patient would respond to chemotherapy. Reducing the levels of DP103 could shrink the tumor, reduce the chance of metastasis and even make patients more receptive to chemotherapy.
The study was published in the prestigious scientific journal, Journal of Clinical Investigation, by a team of scientists lead by Dr Vinay Tergaonkar from IMCB and Dr Alan Prem Kumar from CSI Singapore and NUS. A patent application has also been filed by Dr Kumar on this discovery and is further studying DP103 levels in a variety of cancers.
Source: The above story is based on materials provided by A*Star (Agency for Science, Technology and Research
Full details of the discovery can be accessed here.